Seminar

Size: px

Start display at page:

Download "Seminar"

みいかわたぬき
6 years ago
Views:

1 メディカルセミナー / イブニングセミナー / モーニングセミナーのご案内 Medical Seminar / Evening Seminar / Morning Seminar July 19 (Thu)Medical Seminar / メディカルセミナー MeS-1 11:20~12:10 Room 2 ( 神戸国際展示場 2 号館 1F コンベンションホール南 ) Chair Isamu Okamoto Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University The treatment strategy of NSCLC (focused on ICI) Tony Mok Department of Clinical Oncology, The Chinese University of Hong Kong Co-host: MSD KK. / MSD 株式会社 TAIHO PHARMACEUTICAL CO., LTD. / 大鵬薬品工業株式会社 MeS-2 11:20~12:10 Room 3 ( 神戸国際展示場 1 号館 2F Hall A) Chair Kei Muro Aichi Cancer Center Hospital Impact of primary tumor location on treatment strategy in patients with mcrc Sebastian Stintzing Department of Medicine III, University Hospital, LMU Munich Co-host: Takeda Pharmaceutical Company Limited/ 武田薬品工業株式会社 MeS-3 11:20~12:10 Room 4 ( 神戸国際展示場 1 号館 2F Hall B) Chair Junji Furuse Department of Medical Oncology, Kyorin University Faculty of Medicine Chemotherapy of HCC for recent and future Anthony Boutros El-Khoueiry Division of Medical Oncology, USC Norris Comprehensive Cancer Center Co-host: Bayer Yakuhin, Ltd./ バイエル薬品株式会社 61

2 MeS-4 11:20~12:10 Room 5 ( 神戸国際展示場 2 号館 2F 2A 会議室 ) How to choose the right first-line chemotherapy for metastatic colorectal cancer 進行再発大腸癌一次治療をどう選ぶ? Chair Takako Nakajima Department of Clinical Oncology, St.Marianna University School of Medicine Japanese perspectives Yoshito Komatsu Department of Cancer Center, Hokkaido University Hospital Cancer Center European perspectives Eric Van Cutsem Department of Digestive Oncology, The University of Leuven, Belgium Co-host: TAIHO PHARMACEUTICAL CO., LTD./ 大鵬薬品工業株式会社 MeS-5 11:20~12:10 Room 14 ( 神戸国際展示場 2 号館 2F 2B 会議室 ) Chair Hidenori Inohara Department of Otolaryngology and Head and Neck Surgery, Osaka University, Graduate School of Medicine What s the best treatment sequence in recurrent and metastatic HNSCC? ~Ushered in the new era of Immune-Oncology~ Kevin Harrington The Royal Marsden Hospital The Institute of Cancer Research London, UK Co-host: Merck Serono Co.,Ltd / メルクセローノ株式会社 MeS-6 11:20~12:10 Room 6 ( 神戸国際展示場 2 号館 3F 3A 会議室 ) Exploring a treatment strategy for ALK+NSCLC based on evidence and practice use of ALK inhibitors 今知りたい ALK 陽性非小細胞肺がん治療戦略 Chair Terufumi Kato Department of Thoracic Oncology, Kanagawa Cancer Center Detection and Prediction of ALK-TKI resistance, and the potential therapeutic strategies to overcome the resistance ALK 陽性肺がんにおける耐性機構の検出と予測そして耐性克服法の探索 Ryohei Katayama Div. of Experimental Chemotherapy, Cancer Chemotherapy Center, JFCR Clinical trial update regarding ALK+NSCLC Shirish Madhav Gadgeel Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, USA Co-host: Chugai Pharmaceutical Co., Ltd. / 中外製薬株式会社 62

3 MeS-7 11:20~12:10 Room 7 ( 神戸国際展示場 2 号館 3F 3B 会議室 ) Chair Shunji Takahashi Medical Oncology, The Cancer Institute Hospital Of JFCR Treatment strategy for advanced Melanoma Tatsuya Takenouchi Niigata Cancer Center Hospital Caroline Robert Gustave Roussy Cancer Campus Grand Paris Co-host: Bristol-Myers Squibb K.K. / ブリストルマイヤーズスクイブ株式会社 ONO PHARMACEUTICAL CO., LTD. / 小野薬品工業株式会社 MeS-8 11:20~12:10 Room 8 ( 神戸ポートピアホテル本館 B1F 偕楽 ) Cancer genome profiling test for precision cancer medicine がんゲノム医療実現に向けた取り組みと課題 ~ クリニカルシーケンスエキスパートパネルの進め方 ~ Chair Manabu Muto Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University Experience of clinical cancer sequence クリニカルシーケンスの取り組み事例 Takashi Kohno Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center TR Experience of expert panel ~How Expert panel make a medical decision about cancer genome profile~ エキスパートパネルの進め方 Yutaka Fujiwara Department of Experimental Therapeutics and Department of Thoracic Oncology, National Cancer Center Hospital Co-host: SYSMEX CORPORATION/ シスメックス株式会社 MeS-9 11:20~12:10 Room 9 ( 神戸ポートピアホテル本館 B1F 偕楽 ) Chair Toru Watanabe Hamamatsu Oncology Center Treatment strategy for HER2 positive MBC in EU/Japan Junji Tsurutani Department of Medical Oncology, Kindai University Faculty of Medicine Javier Cortés Medical Oncology Department, Vall d'hebron University Hospital Co-host: Chugai Pharmaceutical Co., Ltd. / 中外製薬株式会社 63

4 MeS-10 11:20~12:10 Room 10 ( 神戸国際会議場 1F メインホール ) Chair Akihiko Gemma Department of Pulmonary Medicine and Oncology. Graduate School of Medicine, Nippon Medical School Past and future treatment strategy for EGFR mutation-positive non-small cell lung cancer EGFR 変異陽性肺がん治療のこれまでとこれから Yasushi Goto Department of Thoracic Oncology, National Cancer Center Hospital Co-host: AstraZeneca K.K./ アストラゼネカ株式会社 MeS-11 11:20~12:10 Room 11 ( 神戸国際会議場 3F 国際会議室 ) What's AYA Patients' issue? From nurse and patient's point of view AYA が抱える課題と現状 : 医療者と患者の立場から Chair Takashi Seto Department of Clinical Oncology, Clinical Research Institute / Department of Thoracic Oncology National, Kyushu Cancer Center Support to AYA Patients: From nursing point of view 思春期若年成人期にあるがん患者への支援 : 看護の視点から Mitsue Maru Konan Women s University, International Nursing Development Issues and current situation of AYA Patients: From patient point of view AYA 世代患者さんの実際 Yohei Nishiguchi Cancer Parents General Incorporated Association Co-host: Chugai Pharmaceutical Co., Ltd. / 中外製薬株式会社 MeS-12 11:20~12:10 Room 12 ( 神戸国際会議場 5F 501 会議室 ) Chair Kazuhito Yamamoto Aichi Cancer Center Hospital r/r PTCL treatment strategy 末梢性 T 細胞リンパ腫 ~ 治療の新展開 ~ Takahiro Yamauchi Faculty of Medical Science, University of Fukui Co-host: MUNDIPHARMA K.K./ ムンディファーマ株式会社 64

5 MeS-13 11:20~12:10 Room 13 ( 神戸国際会議場 5F 502 会議室 ) Chair Hiroshi Ishii Clinical Research and Trial Center, Chiba Cancer Center Step One: Medical Treatments for Gastroenteropancreatic Neuroendocrine Tumor わかりやすい膵消化管神経内分泌腫瘍の治療 Takuji Okusaka Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital Co-host: TEIJIN PHARMA LIMITED/ 帝人ファーマ株式会社 July 20 (Fri)Medical Seminar / メディカルセミナー MeS-14 12:10~13:00 Room 2 ( 神戸国際展示場 2 号館 1F コンベンションホール南 ) Chair Yoichi Nakanishi Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University ~Aiming for Cure~ Future prospects of treatment strategy for the patients with unresectable Stage III NSCLC patients ~ 根治を目指して ~ 切除不能 Ⅲ 期非小細胞肺癌治療今後の展望 Koichi Azuma Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine Yuko Nakayama Department of Radiation Oncology, National Cancer Center Hospital Co-host: AstraZeneca K.K./ アストラゼネカ株式会社 MeS-15 12:10~13:00 Room 3 ( 神戸国際展示場 1 号館 2F Hall A) Chair Kazuhisa Takahashi Department of Respiratory Medicine, Juntendo University Faculty of Medicine & Graduate School of Medicine Treatment strategy for lung cancer in the era of upfront new combination therapy -ICI, TKI and cytotoxic chemotherapy and their combinations 初回 Combination Therapy 時代の肺癌治療戦略 ~ICI TKI そして Cytotoxic による薬物療法 ~ Hidehito Horinouchi Department of Thoracic Oncology, National Cancer Center Hospital Co-host: Eli Lilly Japan K.K./ 日本イーライリリー株式会社 65

6 MeS-16 12:10~13:00 Room 4 ( 神戸国際展示場 1 号館 2F Hall B) Chair Atsushi Sato Department of oncology, Hirosaki University Gastlic Cancer 免疫時代における胃がん薬物療法とは? Ken Kato Nationcal Cancer Center Japan Co-host: Bristol-Myers Squibb K.K. / ブリストルマイヤーズスクイブ株式会社 ONO PHARMACEUTICAL CO., LTD. / 小野薬品工業株式会社 MeS-17 12:10~13:00 Room 5 ( 神戸国際展示場 2 号館 2F 2A 会議室 ) Chair Takayuki Yoshino Department of Gastrointestinal Oncology, National Cancer Center Hospital East The current status and future direction of new drug development for mcrc Josep Tabernero Vall d' Hebron University Hospital Co-host: Eli Lilly Japan K.K./ 日本イーライリリー株式会社 MeS-18 12:10~13:00 Room 14 ( 神戸国際展示場 2 号館 2F 2B 会議室 ) Chair Hiroshi Kitamura Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama Is Immuno-check point inhibitor the Breakthrough for Urothelial Cancer? 免疫療法は本当に尿路上皮癌の Breakthrough なのか? Nobuaki Matsubara Breast and Medical Oncology, National Cancer Center Hospital East Co-host: MSD K.K. / MSD 株式会社 TAIHO PHARMACEUTICAL CO., LTD. / 大鵬薬品工業株式会社 66

7 MeS-19 12:10~13:00 Room 6 ( 神戸国際展示場 2 号館 3F 3A 会議室 ) Chair Yasuhito Terui Hematology Oncology Department, Cancer Institute Hospital, Japanese Foundation for Cancer Research The chemotherapy management of malignant lymphoma ~a nurse s viewpoint~ 悪性リンパ腫の薬物療法マネジメント ~ 看護師の立場から ~ Reiko Nagasaki Nursing Department, Cancer Institute Hospital, Japanese Foundation for Cancer Research The chemotherapy management of malignant lymphoma ~a pharmacist s viewpoint~ 悪性リンパ腫の薬物療法マネジメント ~ 薬剤師の立場から ~ Keiichi Azuma Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research Co-host: Chugai Pharmaceutical Co., Ltd. / 中外製薬株式会社 Nippon Shinyaku Co., Ltd. / 日本新薬株式会社 MeS-20 12:10~13:00 Room 7 ( 神戸国際展示場 2 号館 3F 3B 会議室 ) Chair Hiroyuki Mano National Cancer Research Institute Precision Medicine in the U.S.: Current Status and Future Perspective for Cancer Patients Razelle Kurzrock University of California San Diego Moores Cancer Center Co-host: Chugai Pharmaceutical Co., Ltd. / 中外製薬株式会社 MeS-21 12:10~13:00 Room 8 ( 神戸ポートピアホテル本館 B1F 偕楽 ) Chair Isamu Okamoto Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University Immunotherapy of advanced NSCLC: from 2nd line to near future. Maurice Pérol Medical Oncology Department, Leon Berard Cancer Center, France Co-host: Chugai Pharmaceutical Co., Ltd. / 中外製薬株式会社 MeS-22 12:10~13:00 Room 9 ( 神戸ポートピアホテル本館 B1F 偕楽 ) Chair Yoshinori Ito Breast Medical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research Optimizing outcomes in HR+/HER2 mbc Sunil Verma Department of Oncology, University of Calgary Co-host: Pfizer Japan Inc. / ファイザー株式会社 67

8 MeS-23 12:10~13:00 Room 10 ( 神戸国際会議場 1F メインホール ) Chair Takeshi Kato Colorectal Division, National Hospital Organization Osaka National Hospital New Strategy for Metastatic Colorectal Cancer ~ Need to decide mcrc treatment according to patient's wishes ~ 進行再発大腸癌の新たな治療戦略 ~Shared Decision Making の重要性 ~ Takeo Sato Department of Colorectal Surgery, Kitasato University School of Medicine Co-host: Chugai Pharmaceutical Co., Ltd. / 中外製薬株式会社 MeS-24 12:10~13:00 Room 11 ( 神戸国際会議場 3F 国際会議室 ) Chair Shingo Matsumoto National Cancer Center Hospital East, Division of Thoracic Oncology Liquid Biopsy: Technologies and Clinical Applications Klaus Pantel Institute of Tumor Biology, University Medical Centre Hamburg-Eppendorf, Germany Co-host: IQVIA Services Japan K.K. / IQVIA サービシーズジャパン株式会社 MeS-25 12:10~13:00 Room 12 ( 神戸国際会議場 5F 501 会議室 ) Chair Kensei Yamaguchi Gastroenterological Chemotherapy Department, The Cancer Institute Hospital Of JFCR Cancer immunotherapy ~Current status and Future perspective~ がん免疫療法における最新の知見と今後の展望 Hiroya Taniguchi Department of Clinical Oncology, Aichi Cancer Center Hospital Co-host: MSD K.K. / MSD 株式会社 MeS-26 12:10~13:00 Room 13 ( 神戸国際会議場 5F 502 会議室 ) Chair Yukinori Kurokawa Department of Gastroenterological Surgery, Osaka University, Graduate School of Medicine Perioperative chemotherapy for advanced gastric cancer: Asian Perspectives Yoon-Koo Kang Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine Co-host: Yakult Honsha Co., Ltd./ 株式会社ヤクルト本社 68

9 July 21 (Sat)Medical Seminar / メディカルセミナー MeS-27 12:50~13:40 Room 2 ( 神戸国際展示場 2 号館 1F コンベンションホール南 ) Chair Yuichiro Ohe Department of Thoracic Oncology, National Cancer Center Hospital The New Treatment Option of Cancer Immunotherapy for Non-Small Cell Lung Cancer - Atezolizumab - 非小細胞肺癌におけるがん免疫療法の新たな選択肢 - アテゾリズマブ - Nobuyuki Yamamoto Division of Respiratory Medicine & Medical Oncology, Wakayama Medical University Co-host: Chugai Pharmaceutical Co., Ltd. / 中外製薬株式会社 MeS-28 12:50~13:40 Room 3 ( 神戸国際展示場 1 号館 2F Hall A) Chair Takayuki Yoshino Department of Gastroenterology and Gastrointestinal Oncology / Clinical Research Coordinating Division, National Cancer Center Hospital East The latest trends of adjuvant chemotherapy for colon cancer from IDEA Collaboration, and the international consensus Jean-Yves Douillard Chief Medical Officer, European Society of Medical Oncology ESMO Co-host: Chugai Pharmaceutical Co., Ltd. / 中外製薬株式会社 MeS-29 12:50~13:40 Room 4 ( 神戸国際展示場 1 号館 2F Hall B) Chair Kensei Yamaguchi Department of Gastroenterological Chemotherapy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research Management of Stage IV Gastric Cancer - Established Sequence and Novel Options Florian Lordick University Cancer Center Leipzig UCCL, Germany Co-host: Eli Lilly Japan K.K./ 日本イーライリリー株式会社 69

10 MeS-30 12:50~13:40 Room 5 ( 神戸国際展示場 2 号館 2F 2A 会議室 ) Treatment of cancer associated coagulopathy 固形がんの凝固異常に対する診療 Chair Chikashi Ishioka Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University The purpose of DIC therapy in cancer 固形がんに合併した DIC 治療の意義 Shin Takahashi Department of Medical Oncology, Tohoku University Hospital Management of dissemminatied intravascular coagulation in cancer がんに伴う DIC と治療 Kazuo Tamura General Medical Research Center, Faculty of Medicine, Fukuoka University Co-host: Asahi Kasei Pharma Corporation/ 旭化成ファーマ株式会社 MeS-31 12:50~13:40 Room 14 ( 神戸国際展示場 2 号館 2F 2B 会議室 ) Chair Naoya Masumori Department of Urology, Sapporo Medical University School of Medicine Is RCT the strongest evidence? Conflicts between evidence and practice RCT は最強なのか? Evidence と Practice の葛藤 Nobuaki Matsubara Department of Breast and Medical Oncology, National Cancer Center Hospital East Co-host: Bayer Yakuhin, Ltd./ バイエル薬品株式会社 MeS-32 12:50~13:40 Room 6 ( 神戸国際展示場 2 号館 3F 3A 会議室 ) Chair Koichi Takayama Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine Global Strategies for the Treatment of EGFR Mutation Positive Patient James Chih-Hsin Yang Graduate Institute of Oncology, College of Medicine, National Taiwan University Co-host: Nippon Boehringer Ingelheim Co., Ltd./ 日本ベーリンガーインゲルハイム株式会社 MeS-33 12:50~13:40 Room 7 ( 神戸国際展示場 2 号館 3F 3B 会議室 ) Chair Hirohiko Shibayama Department of Hematology and Oncology, Osaka University Graduate School of Medicine Hodgkin Lymphoma ホジキンリンパ腫 Andres Forero-Torres University of Alabama at Birmingham Co-host: Takeda Pharmaceutical Company Limited/ 武田薬品工業株式会社 70

11 MeS-34 12:50~13:40 Room 8 ( 神戸ポートピアホテル本館 B1F 偕楽 ) Second-Line Strategies in the Treatment of Metastatic Colorectal Cancer 切除不能進行再発大腸癌二次治療における治療戦略 Chair Narikazu Boku Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital Second line chemotherapy for metastatic colorectal cancer - translating clinical data into daily practice - 大腸がん二次治療 ~ データを実地臨床に生かすには ~ Hiroya Taniguchi Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East 愛知県がんセンター中央病院薬物療法部 To master second line chemotherapy for metastatic colorectal cancer Yuki s opinion 大腸がん二次化学療法を使いこなすために ~ 結城はこう考える ~ Satoshi Yuki Department of Gastroenterology and Hepatology, Hokkaido University Hospital Co-host: Sanofi K.K. / サノフィ株式会社 Yakult Honsha Co., Ltd./ 株式会社ヤクルト本社 MeS-35 12:50~13:40 Room 9 ( 神戸ポートピアホテル本館 B1F 偕楽 ) Chair Kazuhisa Takahashi Graduate School of Medicine Respiratory Internal, Juntendo University Hospital The role of Nivolumab in advanced NSCLC Matthew Gubens Thoracic Medical Oncology University of California, San Francisco Co-host: Bristol-Myers Squibb K.K. / ブリストルマイヤーズスクイブ株式会社 ONO PHARMACEUTICAL CO., LTD. / 小野薬品工業株式会社 MeS-36 12:50~13:40 Room 10 ( 神戸国際会議場 1F メインホール ) Chair Koichi Goto Department of Thoracic Oncology, National Cancer Center Hospital East Collaboration beyond specialty in lung cancer treatment - febrile neutropenia and oral care 肺癌治療における発熱性好中球減少症と口腔ケア Haruyasu Murakami Division of Thoracic Oncology, Shizuoka Cancer Center / Takashi Yurikusa Division of Dentistry and Oral Surgery, Shizuoka Cancer Center Co-host: Eli Lilly Japan KK/ 日本イーライリリー株式会社 71

12 MeS-37 12:50~13:40 Room 11 ( 神戸国際会議場 3F 国際会議室 ) Chair Shinsuke Iida Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences Pathophysiology and management of bone disease in multiple myeloma 多発性骨髄腫骨病変の病態とマネジメント Masahiro Abe Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School Co-host: Daiichi Sankyo Co., Ltd. / 第一三共株式会社 MeS-38 12:50~13:40 Room 12 ( 神戸国際会議場 5F 501 会議室 ) Chair Yasuhiro Kodera Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine 2 Tips for success in Precision medicine ~Pan-tumor approach & in-house preparation~ Tips for success in Precision medicine 癌腫横断的な視野と院内体制整備に向けて ~ Hideaki Bando Department of Gastrointestinal Oncology, National Cancer Center Hospital East Co-host: MSD K.K. / MSD 株式会社 MeS-39 12:50~13:40 Room 13 ( 神戸国際会議場 5F 502 会議室 ) Chair Noriyuki Katsumata Department of Medical Oncology, Nippon Medical School Musashikosugi Hospital Geriatric oncology and palliative care in the real small world リアルスモールワールドでの高齢者がん診療と疼痛緩和 Koichi Kitagawa Division of Medical Oncology, Kobe Minimally Invasive Cancer Center Co-host: Hisamitsu Pharmaceutical Co., Inc. / 久光製薬株式会社 Kyowa Hakko Kirin Co., Ltd. / 協和発酵キリン株式会社 72

13 MeS-40 12:50~13:40 Room 15 ( 神戸国際会議場 5F 504 会議室 +505 会議室 ) TAILORx を踏まえた早期乳癌の個別化治療 Chair Hironobu Minami Medical Oncology / Hematology, Kobe University Graduate School Medicine 非劣性試験 TAILORx の統計的側面 Satoshi Morita Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine OncotypeDX の最新知見と今後の展望 Tatsuya Toyama Department of Breast Surgery, Nagoya City Univ Graduate School of Medical Sciences Co-host: Genomic Health K.K./ ジェノミックヘルス株式会社 SRL, Inc. / 株式会社エスアールエル July 19 (Thu)Evening Seminar / イブニングセミナー ES-1 16:20~17:10 Room 3 ( 神戸国際展示場 1 号館 2F Hall A) Cancer Associated Thrombosis がんと血栓症 Chair Mitsuru Sasako Department of Surgery, Yodogawa Christian Hospital Pathological condition of sudden death by acute pulmonary thromboembolism 担がん患者が急性広範性肺血栓塞栓症により突然死する病態 Ayako Ro Department of Legal Medicine, St. Marianna University School of Medicine Mechanism and management in cancer-associated thrombosis がん関連血栓症の病態と管理 Mikio Mukai Department of Medical Checkup, Osaka Prefectural Hospital Organization, Osaka International Cancer Institute Co-host: DAIICHI SANKYO CO., LTD./ 第一三共株式会社 73

14 ES-2 16:20~17:10 Room 4 ( 神戸国際展示場 1 号館 2F Hall B) Chair Takako Nakajima Department of Clinical Oncology, St. Marianna University School of Medicine Regorafenib for metastatic Colorectal Cancer - Up to date - 転移性大腸癌におけるレゴラフェニブ療法 ~ 上手に使うためには?~ Kentaro Yamazaki Division of Gastrointestinal Oncology, Shizuoka Cancer Center Co-host: Bayer Yakuhin, Ltd./ バイエル薬品株式会社 ES-3 16:20~17:10 Room 5 ( 神戸国際展示場 2 号館 2F 2A 会議室 ) Chair Makoto Tahara Department of Head and Neck Medical Oncology, National Cancer Center Hospital East Immunotherapy and Head and Neck Cancer Are we finally making progress toward better outcomes? 頭頸部がん治療におけるがん免疫療法 Robert Haddad Dana-Farber Cancer Institute Co-host: Bristol-Myers Squibb K.K. / ブリストルマイヤーズスクイブ株式会社 ONO PHARMACEUTICAL CO., LTD. / 小野薬品工業株式会社 ES-4 16:20~17:10 Room 6 ( 神戸国際展示場 2 号館 3F 3A 会議室 ) Chair Kei Muro Department of Clinical Oncology and Outpatient Treatment Center, Aichi Cancer Center Hospital Gastric cancer treatment update - New insights into clinical practice - 胃癌治療 update - 最新の知見を日常臨床にどう活かすか?- Narikazu Boku Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital Co-host: TAIHO PHARMACEUTICAL CO., LTD./ 大鵬薬品工業株式会社 74

15 ES-5 16:20~17:10 Room 7 ( 神戸国際展示場 2 号館 3F 3B 会議室 ) Chair Akira Kawai Department of Musculoskeletal oncology and Rehabilitation, Rare Cancer Center, National Caner Center Hospital / The role of anti-pd-l1 antibody in immuno-oncology (the effacy of avelumab, first anti-pd-l1 antibody in Japan to Merkel cell caricinoma) 腫瘍免疫における抗 PD- L1 抗体の役割 ( 本邦初の抗 PD-L1 抗体薬アベルマブとメルケル細胞がんでの有用性 ) Hiroyoshi Nishikawa Division of Cancer Immunology, Research Institute Exploratory Oncology Research & Clinical Trial Center EPOC National Cancer Center; Department of Immunology, Nagoya University Graduate School of Medicine TR Yoshio Kiyohara Shizuoka Cancer Center, Dermatology Division Co-host: Merck Serono Co.,Ltd / メルクセローノ株式会社 Pfizer Japan Inc. / ファイザー株式会社 ES-6 16:20~17:10 Room 8 ( 神戸ポートピアホテル本館 B1F 偕楽 ) Chair Kazuhiko Nakagawa Kindai University Faculty of Medicine The Evolving Power of Immunotherapy -Transforming Outcomes in Advanced Lung Cancer- Solange Peters Centre Hospitalier Universitaire Vaudois CHUV Oncology Department Co-host: Bristol-Myers Squibb K.K. / ブリストルマイヤーズスクイブ株式会社 ONO PHARMACEUTICAL CO., LTD. / 小野薬品工業株式会社 ES-7 16:20~17:10 Room 9 ( 神戸ポートピアホテル本館 B1F 偕楽 ) Chair Shigehira Saji Department of Medical Oncology, Fukushima Medical University Predicting survival outcome and treatment benefit in HR+/HER2-negative metastatic breast cancer Aleix Prat Head Medical Oncology Department, Hospital Clinic, University of Barcelona, Spain Co-host: AstraZeneca K.K./ アストラゼネカ株式会社 75

16 ES-8 16:20~17:10 Room 10 ( 神戸国際会議場 1F メインホール ) Chair Hiroji Iwata Breast Oncology, Aichi Cancer Center Hospital The Wonders of PFS/OS (as the Primary endpoint)in Clinical trials 臨床試験における PFS/OS の不思議 Satoshi Morita Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine Tatsuya Toyama Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences Co-host: Chugai Pharmaceutical Co., Ltd. / 中外製薬株式会社 ES-9 16:20~17:10 Room 11 ( 神戸国際会議場 3F 国際会議室 ) Chair Tetsuya Mitsudomi Division of Theracic Surgery, Department Surgery, Kindai University Faculty of Medicine ALK+ Non-Small Cell Lung Cancer -The unsolved issues in Japanese practice- ALK 陽性非小細胞肺癌 - 国内臨床における未解決の課題 - Takashi Seto Department of Thoracic Oncology, National Kyushu Cancer Center Co-host: Novartis Pharma K.K./ ノバルティスファーマ株式会社 ES-10 16:20~17:10 Room 12 ( 神戸国際会議場 5F 501 会議室 ) Chair Takahiro Yamauchi Hematology and Oncology, First Department of Internal Medicine, General Medicine, Faculty of Medical Science, University of Fukui 1 Great expectations in AML Courtney D. DiNardo Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center Co-host: AbbVie GK / アッヴィ合同会社 ES-11 16:20~17:10 Room 13 ( 神戸国際会議場 5F 502 会議室 ) Chair Akihito Tsuji Department of Clinical Oncology, Faculty of Medicine, Kagawa University 辻 Precision Medicine for Gastrointestinal Cancer 消化器がんに対する Precision Medicine Shigemi Matsumoto Department of Medical Oncology, Graduate School of Medicine, Kyoto University Co-host: MOCHIDA PHARMACEUTICAL CO., LTD./ 持田製薬株式会社 Pfizer Japan Inc. / ファイザー株式会社 76

17 July 20 (Fri)Evening Seminar / イブニングセミナー ES-12 17:10~18:00 Room 3 ( 神戸国際展示場 1 号館 2F Hall A) Chair Chikashi Ishioka Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University The importance of optimal drug sequencing in mcrc: Biological rationales for the patients benefit and future perspective Heinz-Josef Lenz Norris Comprehensive Cancer Center, University of Southern Carolina, Los Angeles, CA, USA Co-host: Merck Serono Co.,Ltd / メルクセローノ株式会社 ES-13 17:10~18:00 Room 4 ( 神戸国際展示場 1 号館 2F Hall B) Chair Akira Inoue Department of Palliative Medicine, Tohoku University School of Medicine The newest opioid analgesic ~use Tapentadol thoughtfully~ 新しいオピオイド ~ タペンタドールを使いこなす ~ Kinomi Yomiya Division of Palliative care, Saitama Cancer Center Co-host: Mundipharma K.K. / ムンディファーマ株式会社 77

18 ES-14 17:10~18:40 Room 5 ( 神戸国際展示場 2 号館 2F 2A 会議室 ) For the Management of Skin Toxicity Associated with Immune Checkpoint Inhibitors and concomitant drugs A feedback from the Consensus meeting 2018 with Volunteer Medical Oncologists and Dermatologists 皮膚科腫瘍内科有志コンセンサス会議の報告 - 免疫チェックポイント阻害剤に起因する皮膚障害とその対策 - Chairs Nobuyuki Yamamoto Respiratory Medicine and Medical Oncology, Wakayama Medical University Makoto Kawashima Tokyo Women's Medical University Opening address: Skin Toxicity Associated with Immune Checkpoint Inhibitors and concomitant drugs. Case review of experience in Hyogo Cancer Center オープニングアドレス : 兵庫県立がんセンターにおける症例報告 Miyako Satouchi Department of Thoracic Oncology, Chemotherapy, Hyogo Cancer Center Skin Toxicity Associated with Immune Checkpoint Inhibitors and concomitant drugs. Overview of symptoms 免疫チェックポイント阻害薬使用症例における併用薬による皮疹の実際 Yoshio Kiyohara Department of Dermatology, Shizuoka Cancer Center Overview of Skin Toxicity with Immune Checkpoint Inhibitors 免疫チェックポイント阻害薬の皮膚関連副作用概論 Naoya Yamazaki Department of Dermatologic Oncology, National Cancer Center Hospital Panel Discussion Discussant / 総合討議ディスカッサント Tomohiro Nishina Department of Gastroenterology, National Hospital Organization Shikoku Cancer Center Yuki Kogure Department of Pharmacy, National Hospital Organization Shikoku Cancer Center Co-host: Non-profit Organization JASMIN/ 特定非営利活動法人 JASMIN 78

19 ES-15 17:10~18:00 Room 14 ( 神戸国際展示場 2 号館 2F 2B 会議室 ) Chair Taroh Satoh Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine How to decipher New Gastric Cancer Treatment Guidelines : From major to minor changes 新しい胃癌治療ガイドラインをどう読み解くかど真ん中からニッチまで Eiji Oki Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University Co-host: Nippon kayaku Co., Ltd./ 日本化薬株式会社 ES-16 17:10~18:00 Room 6 ( 神戸国際展示場 2 号館 3F 3A 会議室 ) Chair Shinsuke Iida Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences Treatment Strategy for Transplant Ineligible Newly Diagnosed Multiple Myeloma with Novel Agents 新規薬剤を用いた移植非適応未治療多発性骨髄腫の治療戦略 Hideto Tamura Department of Hematology, Nippon Medical School Co-host: Celgene K.K./ セルジーン株式会社 ES-17 17:10~18:00 Room 7 ( 神戸国際展示場 2 号館 3F 3B 会議室 ) Chair Toshiyuki Sumi Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine Chemotherapy for Cervical Cancer ~Is CPT-11/NDP necessary?~ 子宮頸癌の化学療法 ~CPT-11/NDP の有用性の検証 ~ Nobuhiro Takeshima Department of Gynecological Oncology, Japanese Foundation For Cancer Research Cancer Institute Hospital Co-host: Nichi-Iko Pharmaceutical Co., Ltd./ 日医工株式会社 79

20 ES-18 17:10~18:40 Room 8 ( 神戸ポートピアホテル本館 B1F 偕楽 ) The positioning of Immunecheckpoint inhibitor and biomarkers in NSCLC 非小細胞肺癌における免疫チェックポイント阻害剤の位置づけとバイオマーカー Chair Tetsuya Mitsudomi Division of Thoracic Surgery Department of Surgery, Kindai University Faculty of Medicine Implementation of genomic medicine in non-small cell lung cancer 非小細胞肺癌におけるゲノム医療の実装 Kazuto Nishio Department of Genome Biology, Kindai University Faculty of Medicine Recent Progress for immunecheckpoint inhibitor in NSCLC 非小細胞肺癌における免疫チェックポイント阻害薬の展開 Kazuo Kasahara Respiratory Medicine, Kanazawa University Hospital Co-host: MSD K.K. / MSD 株式会社 TAIHO PHARMACEUTICAL CO., LTD. / 大鵬薬品工業株式会社 ES-19 17:10~18:00 Room 9 ( 神戸ポートピアホテル本館 B1F 偕楽 ) Chair Hironobu Minami Medical Oncology / Hematology, Kobe University Graduate School Medicine Current issues in outpatient chemotherapy 外来化学療法の現状と課題 Hikaru Nakajima Hematology Medical Oncology, St. Luke's University Hospital, Lewis Katz School of Medicine at Temple University Hematology Medical Oncology, St. Luke's University Hospital, Lewis Katz School of Medicine at Temple University Hisashi Ishikura Department of Surgery, Division of Thoracic Surgery, Tokushima Red Cross Hospital Masanori Toyoda Medical Oncology Hematology, Kobe University Graduate School Medicine Yong-Il Kim Medical Oncology Yodogawa Christian Hospital Co-host: Kyowa Hakko Kirin Co.,Ltd/ 協和発酵キリン株式会社 80

21 ES-20 17:10~18:00 Room 11 ( 神戸国際会議場 3F 国際会議室 ) Chair Eishi Baba Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University Treatment of Soft Tissue Sarcoma 悪性軟部肉腫の治療戦略 Kan Yonemori Department of Breast and Medical Oncology Experimental Therapeutics, National Cancer Center / Co-host: TAIHO PHARMACEUTICAL CO., LTD./ 大鵬薬品工業株式会社 ES-21 17:10~18:00 Room 12 ( 神戸国際会議場 5F 501 会議室 ) How can we apply The Japanese Breast Cancer Society Guideline 2018 to clinical practice? 乳癌診療ガイドライン 2018 年版をどう臨床に役立てるか? Chair Hiroji Iwata Aichi Cancer Center, Department of Breast Oncology What is new? ; The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2018 edition 乳癌診療ガイドライン : 薬物療法改定のポイント Junji Tsurutani Department of Medical Oncology, Kindai University Faculty of Medicine How can we make the best use of molecular target drugs for treatment of postmenopausal hormone receptor positive advanced breast cancer? 閉経後ホルモン受容体陽性進行再発乳癌の治療に分子標的治療薬をどう活かすか? Takahiro Nakayama Osaka International Cancer Institute Breast and Endocrine Surgery Co-host: Novartis Pharma K.K./ ノバルティスファーマ株式会社 81

22 ES-22 17:10~18:00 Room 13 ( 神戸国際会議場 5F 502 会議室 ) The Latest Updates and Clinical Practice in ALK/ROS1-positive lung cancer ALK/ROS1 肺癌における最新情報と実臨床 Chair Yuichiro Ohe Division of Thoracic Oncology, National Cancer Center Hospital Recent Updates in Oncogene-Driven Lung Cancer What's remaining issue? Driver Oncogene 陽性肺癌の最新データと残された課題 Hiroaki Akamatsu Third Department of Internal Medicine, Wakayama Medical University Optimal diagnostics and treatment of ROS1-positive lung cancer ROS1 肺がんの最適な診断と治療戦略 Toyoaki Hida Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya Co-host: Pfizer Japan Inc. / ファイザー株式会社 Merck Serono Co., Ltd./ メルクセローノ株式会社 July 20 (Fri)Morning Seminar / モーニングセミナー MoS-1 7:30~8:20 Room 4 ( 神戸国際展示場 1 号館 2F Hall B) Chair Miyako Satouchi Department of Thoracic Oncology, Hyogo Cancer Center Points to note in genetic testing by Next Generation Sequencing for NSCLC in clinical practice and BRAF V600E mutation as therapeutic target 次世代シークエンシングによる肺がん検査の留意点と治療標的としての BRAF V600E 遺伝子 Yasuhiro Koh Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University Co-host: Novartis Pharma K.K./ ノバルティスファーマ株式会社 MoS-2 7:30~8:20 Room 14 ( 神戸国際展示場 2 号館 2F 2B 会議室 ) Chair Yuichi Ando Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital Impact of TKIs on primary organs -Cardio-Renal Association for oncologists- 分子標的治療薬の臓器への影響を考察する ~ 腫瘍内科医が知っておきたい心腎連関を中心に ~ Mototsugu Oya Department of Urology, Keio University School of Medicine Mikio Mukai Department of Medical Checkup, Osaka International Cancer Institute Co-host: Bayer Yakuhin, Ltd./ バイエル薬品株式会社 82

23 MoS-3 7:30~8:20 Room 7 ( 神戸国際展示場 2 号館 3F 3B 会議室 ) Chair Takeshi Kuwata Department of Pathology and Clinical Laboratories, National Cancer Hospital East Future perspectives of liquid biopsy for cancer precision medicine リキッドバイオプシーによるクリニカルシークエンスへ向けての展望 Kazuko Sakai Department of Genome Biology, Kindai University Faculty of Medicine Co-host: Roche Diagnostics K.K./ ロシュダイアグノスティックス株式会社 MoS-4 7:30~8:20 Room 9 ( 神戸ポートピアホテル本館 B1F 偕楽 ) Chair Aiko Okamoto The Jikei University School of Medicine New prospective of platinum sensitive recurrent ovarian cancer プラチナ感受性再発卵巣がんの新たな展望 Richard T. Penson Harvard Medical School Medical Gyn Onc Massachusetts General Hospital Co-host: AstraZeneca K.K./ アストラゼネカ株式会社 MoS-5 7:30~8:20 Room 11 ( 神戸国際会議場 3F 国際会議室 ) Chair Fumio Imamura Department of Medical Oncology, Osaka International Cancer Institute Benefit and risk for nivolumab オプジーボの Benefit and Risk 集団をあぶり出す Hidetoshi Hayashi Department of Medical Oncology, Kindai University Faculty of Medicine Co-host: ONO PHARMACEUTICAL CO., LTD. / 小野薬品工業株式会社 Bristol-Myers Squibb K.K. / ブリストルマイヤーズスクイブ株式会社 83

24 MoS-6 7:30~8:20 Room 12 ( 神戸国際会議場 5F 501 会議室 ) Multidisciplinary approach to soft tissue sarcoma -Benefits and case study- 悪性軟部腫瘍への集学的アプローチ - その意義と実例 - Chair Akira Kawai Department of Musculosleletal Oncology and Rehabilitation, National Cancer Center Hospital Benefits of the sarcoma center establishment and future perspectives of soft tissue sarcoma treatment サルコーマセンター開設の意義と悪性軟部腫瘍診療の今後の展望 Satoshi Tsukushi Department of Orthopedic Surgery, Aichi Cancer Center Hospital Involvement of medical oncologists in the multidisciplinary approach to soft tissue sarcoma 腫瘍内科医の悪性軟部腫瘍診療連携への関わり Masashi Ando Department of Clinical Oncology, Aichi Cancer Center Hospital Co-host: Novartis Pharma K.K./ ノバルティスファーマ株式会社 MoS-7 7:30~8:20 Room 13 ( 神戸国際会議場 5F 502 会議室 ) Future treatment strategy for ER+ metastatic breast cancer ~New role of chemotherapy~ これからの ER 陽性乳癌の治療戦略 ~ 化学療法に求められる役割 ~ Chair Yoshinori Ito Breast Medical Oncology, Breast Cancer Center, Cancer Institute Hospital New trends of Endocrine resistance in ER+ Breast Cancer 内分泌療法抵抗性の新潮流 Shin-ichi Hayashi Department of Molecular and Functional Dynamics, Tohoku University Graduate School of Medicine Reconsidering the treatment strategy for ER+ Breast Cancer ER 陽性乳癌の治療ストラテジーを再考する Masato Takahashi Hokkaido Cancer Center Co-host: Eisai Co., Ltd./ エーザイ株式会社 MoS-13 7:30~8:20 Room 2 ( 神戸国際展示場 2 号館 1F コンベンションホール南 ) Chair Sadakatsu Ikeda Tokyo Medical Dental University, Cancer Center Clinical Validation of Guardant360 and Current clinical utility of liquid biopsy Justin Odegaard Guardant Health Inc. Co-host: Guardant Health, Inc. 84

25 July 21 (Sat)Morning Seminar / モーニングセミナー MoS-8 7:30~8:20 Room 5 ( 神戸国際展示場 2 号館 2F 2A 会議室 ) Chair Masatoshi Kudo Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine Systemic Therapy for HCC: Integrating New Data into Practice Richard S. Finn Geffen School of Medicine at UCLA Co-host: Eisai Co., Ltd./ エーザイ株式会社 MoS-9 7:30~8:20 Room 6 ( 神戸国際展示場 2 号館 3F 3A 会議室 ) Challenge! BRAF as the driver gene opens up the future through Melanoma to NSCLC 挑む!Driver 遺伝子 BRAF が切り開く未来 ~ メラノーマから肺癌へ ~ Chairs Hisashi Uhara Department of Dermatology, Sapporo Medical University School of Medicine Kazuhiko Nakagawa Department of Medical Oncology, Kindai University Faculty of Medicine BRAF as the driver gene Driver 遺伝子としての BRAF Seiji Yano Division of Medical Oncology, Kanazawa University Cancer Research Institute The bridge between Melanoma and NSCLC Evidence and Clinical Practice メラノーマから肺癌への架け橋 ~ エビデンスに基づいた臨床経験 ~ Yutaka Fujiwara Department of Experimental Therapeutics Department of Thoracic Oncology, National Cancer Center Hospital Co-host: Novartis Pharma K.K./ ノバルティスファーマ株式会社 MoS-10 7:30~8:20 Room 7 ( 神戸国際展示場 2 号館 3F 3B 会議室 ) Gene Panel to Whole Exome Sequence: Can we adapt this for cancer genomic testing? がんゲノム医療の今後遺伝子パネルからWhole Exome Sequenceへ : 臨床実装への挑戦 Hiroshi Nishihara Genomics Unit, Keio Cancer Center, Keio University School of Medicine Co-host: Illumina K.K./ イルミナ株式会社 85

26 MoS-11 7:30~8:20 Room 12 ( 神戸国際会議場 5F 501 会議室 ) Gastroenteropancreatic neuroendocrine tumor ~ Delve into deeper! Seek for the optimal treatment strategy ~ 膵消化管神経内分泌腫瘍 ~ 徹底究明! 最適な治療戦略を考える ~ Chair Junji Furuse Department of Medical Oncology, Kyorin University School of Medicine Surgical treatment of GI-NET according to the progression 進行度に応じた消化管 NET の外科治療 Tsuyoshi Konishi Colorectal Division, Department of Gastroenterological Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research Selecting best therapeutic options for patients with advanced GEP NET GEP NET の患者に対する最適な治療法の選択 Masafumi Ikeda Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East Co-host: Novartis Pharma K.K./ ノバルティスファーマ株式会社 MoS-12 7:30~8:20 Room 13 ( 神戸国際会議場 5F 502 会議室 ) Chair Kenichi Ishizawa Department of Neurology, Hematology, metabolism, Endocrinology and Diabetology, Yamagata University Faculty of Medicine Risk management of Tumor lysis syndrome 腫瘍崩壊症候群のリスクマネジメント Michihide Tokuhira Department of Hematology, Saitama Medical Center, Saitama Medical University Co-host: Sanofi K.K./ サノフィ株式会社 86

Evening Seminar Day2 (July 20)

Evening Seminar Day2 (July 20) July 20 (Fri)Evening Seminar / イブニングセミナー ES-12 17:10~18:00 Room 3 ( 神戸国際展示場 1 号館 2F Hall A) Chair Chikashi Ishioka Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University